Shares of Vitae Pharmaceuticals Inc. (VTAE) are up over 58% in extended trading on Wednesday, following positive top-line results from the company's 4-week phase 2a proof-of-concept clinical trial of VTP-43742 in psoriatic patients.
from RTT - Biotech http://ift.tt/1RnHDw9
via IFTTT
No comments:
Post a Comment